Cas:114960-98-4 4-(azepan-1-yl)butan-1-ol manufacturer & supplier

We serve Chemical Name:4-(azepan-1-yl)butan-1-ol CAS:114960-98-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

4-(azepan-1-yl)butan-1-ol

Chemical Name:4-(azepan-1-yl)butan-1-ol
CAS.NO:114960-98-4
Synonyms:4-azaperhydroepinylbutan-1-ol;4-hexahydroazepin-1-yl-butan-1-ol
Molecular Formula:C10H21NO
Molecular Weight:171.28000
HS Code:2933990090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:264.91ºC at 760 mmHg
Density:0.934g/cm3
Index of Refraction:1.472
PSA:23.47000
Exact Mass:171.16200
LogP:1.57280

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 4-azaperhydroepinylbutan-1-ol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-hexahydroazepin-1-yl-butan-1-ol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-azaperhydroepinylbutan-1-ol Use and application,4-azaperhydroepinylbutan-1-ol technical grade,usp/ep/jp grade.


Related News: Now that Alexion’s Soliris is in AstraZeneca’s hands, the drugmaker is counting on the C5 inhibitor to help push it toward billions in sales in just a few years. But a prominent drug pricing watchdog is raising a red flag over its costs for patients with a rare neuromuscular disorder. 2-METHOXY-5-TRIFLUOROMETHYLPHENYLBORONIC ACID manufacturers “This is the beginning of the next chapter of growth for BetterUp, and we are not slowing down,” said Alexi Robichaux, CEO and co-founder of BetterUp. “Though we have done business in Europe since 2016, we are committing to a new level of investment in our customers, coaches, and communities by establishing offices in Munich and London. 2-[(2,6-dimethylpyridin-4-yl)methyl]azepane suppliers About eight months after originally teaming up on neuromuscular diseases, Takeda and PeptiDream have expanded the pact to include several central nervous system targets, while revealing the tie-up could be worth more than $3.5 billion. 9-methyl-9H-fluorene-2,7-diol vendor & factory.